EZZ's Principal Activity is the distribution of skin care products and production and distribution of consumer health products in Australia and New Zealand.
|Bid / Ask||-|
|Volume (4w avg)|
|vs Sector (1yr)||-|
|vs ASX 200 (1yr)||-85.50%|
|ASX Rank||2,196 of 2,297|
|NTA per share||$0.00|
EZZ is not covered by a major broker, or data from most recent compilation was omitted due to not meeting QA guidelines.
EZZ Life Science Holdings Limited (EZZ) is wholesale distributor of a range of skin care products under the EAORON brand to pharmacies, supermarkets and specialist retailers in Australia and New Zealand. It also develops, produces and distributes consumer health products under its own brand, EZZ, to retailers in Australia and New Zealand as well as consumers in China, with plans to expand to other international markets.
No incorporation details available.
DPS and Yield calculations use the Pay Date.
|No dividends paid.|
See Upcoming Dividends for all ASX companies.
|Ms Philippa Mary Lewis||Non-Executive Chairman,Non-Executive Director||Oct 2020||
Ms Philippa Mary Lewis
Non-Executive Chairman,Non-Executive Director
Ms Lewis has over 30 years of experience in the life science and digital health care sector. She has founded multiple companies, led local and North American IPOs, reverse mergers, complex M&A transactions, strategic capital management and multilateral joint ventures within North America, Europe, China and Australia. Ms. Lewis acted as a director of ASX listed MedTech company Simavita Ltd (ASX: SVA) between 2008 and 2016. She also chaired the board of Lifespot Health Ltd (ASX: LSH) between May and December 2017. Ms Lewis is currently chair of Imunexus Ltd, a public unlisted company in the oncology therapeutics sector and has served on the board of the Medical Technology Association of Australia. Ms Lewis has completed both the Directors and Chair course. She has been nominated as Zurich Business Leader of the Year and Telstra Business - Woman of the Year. She has also been appointed as a grants assessor for the NSW Government MedTech and Pharma Growth Centre. She is also Member of Risk Committee & Human Resources Committee of EZZ.
|Mr Ivan Oshry||Non-Executive Director||Oct 2020||
Mr Ivan Oshry
Mr Oshry has more than 30 years of experience of legal practice in Australia and internationally, focusing in commercial and corporate law. Mr Oshry was formerly a senior partner at Fluxmans Attorneys in Johannesburg and headed up the corporate department at Kemp Strang (which has since merged with Thomson Geer) in Sydney. He has acted as legal adviser to multiple IPO's both locally and internationally and advised on a number of transactions for both listed and unlisted entities. He has been a guest speaker at various local and international conferences dealing with mergers and acquisitions and equity capital market topics. Mr Oshry sits on the board of a number of private and publicly unlisted companies. He was elected to International Who's Who in Finance and Industry in 2002. He is also Chair of the Risk Committee and member of the Human Resources Committee of EZZ.
|Ms Lily (Hao) Huang||Non-Executive Director||Oct 2020||
Ms Lily (Hao) Huang
Ms Huang has over 20 years of experience in senior management roles in the wealth management and banking industry. She has been working with Citi Group Australia since 2017 as Vice President of the APAC Desk of the Investment Partnerships Division. Previously, she acted at National Australia Bank as the director of migrant banking between 2011 and 2017. She also performed various management roles at other financial institutions including premium banking division of Westpac Bank and lending division of Commonwealth Bank. Ms Huang was awarded top 10 Australia Chinese Entrepreneurs in 2015, included in the Australia Chinese Historical Yearbook Ranking 2015.Ms Huang has over 20 years of experience in senior management roles in the wealth management and banking industry. She has been working with Citi Group Australia since 2017 as Vice President of the APAC Desk of the Investment Partnerships Division. Previously, she acted at National Australia Bank as the director of migrant banking between 2011 and 2017. She also performed various management roles at other financial institutions including premium banking division of Westpac Bank and lending division of Commonwealth Bank. Ms Huang was awarded top 10 Australia Chinese Entrepreneurs in 2015, included in the Australia Chinese Historical Yearbook Ranking 2015. She is also member of the Risk Committee and chair of the Human Resources Committee of EZZ.
|Mr Luis Fernando Rodriguez-Bravo||Chief Executive Officer,Executive Director||Jul 2020||
Mr Luis Fernando Rodriguez-Bravo
Chief Executive Officer,Executive Director
Mr Rodriguez-Bravo has over 20 years of senior leadership experience across a number of industries including skin care and consumer health segment both domestically and internationally. Mr Rodriguez-Bravo joined the Company in 2018. Under the leadership of Mr Rodriguez-Bravo, the Company has entered into distribution contracts with pharmaceutical groups and customers, enhanced the brand position of EAORON in Australia and New Zealand markets.
|Mr Mark (Qizhou) Qin||Chief Operating Officer,Executive Director||Sep 2018||
Mr Mark (Qizhou) Qin
Chief Operating Officer,Executive Director
Mr Qin has experience in skin care and consumer health industry. He has a background in management consulting, experience in sales and marketing and a technical understanding of the industry segments. Prior to co-founding the Company in 2018, he co-founded a marketing consulting firm, CE International, which was rated as one of the Top 10 Consulting Firms in China in 2010. Prior to that, he was personally awarded as the "Top Research Analyst" by the Sales and Marketing Magazine in 2006. Mr Qin also authored five books in sales and marketing for the health care industry between 2003 and 2008.
|Ms Natalie Sylvia Climo||Company Secretary||N/A|
The current holdings of EZZ directors.
|Director||Last Notice||Direct Shares||Indirect Shares||Options||Convertibles|
|Lily (Hao) Huang||27/10/2020||0||N/A||N/A||N/A|
|Mark (Qizhou) Qin||01/09/2018||N/A||11,344,000||N/A||N/A|
No Substantial Shareholders for EZZ in our database.
12 month transaction history compiled from ASX announcements.
|Date||Name||Bought||Previous %||New %|
|04-03-21||Credit Suisse Holdings (Australia) Limited||2,374,786||--||5.65|
|03-03-21||JNJ Mok Pty Ltd||11,344,000||--||27.01|
|03-03-21||Macquarie Holdings Pty Ltd||17,016,000||--||40.51|
12 month transaction history compiled from ASX announcements.
|Date||Name||Sold||Previous %||New %|
|05-03-21||Credit Suisse Holdings (Australia) Limited||2,374,786||5.65||--|
All data on this page is supplied by the ASX, Morningstar and Market Index. Read the disclaimer.